Nusinersen is administered via an intrathecal injection, directly into the cerebrospinal fluid, allowing it to reach the central nervous system. By binding to a specific sequence in the SMN2 pre-mRNA, it alters the splicing process, leading to the inclusion of exon 7. This modification increases the production of functional SMN protein, which is crucial for the survival and function of motor neurons.
